{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:18Z","timestamp":1787026998610,"version":"build-2736575974"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Acute kidney injury and chronic kidney disease is common in multiple myeloma. Fludarabine which is part of lymphodepletion before CAR-T cell therapy is renally eliminated and its use is not recommended for patients with severe renal impairment defined as a glomerular filtration rate below 30ml\/min\/1.73m\n                    <jats:sup>2<\/jats:sup>\n                    . We administered fludarabine to a 58-year-old female patient with myeloma-associated severe renal impairment as part of lymphodepletion before Idecabtagen vicleucel infusion. Fludarabine was administered in reduced dose (15mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) and cyclophosphamide with a dose of 300mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    followed by hemodialysis over six hours using a larger filter (FX-100). The therapy was well tolerated with excellent CAR-T cell expansion and complete remission which is ongoing now beyond 12 months.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2023.1288764","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T08:58:35Z","timestamp":1699952315000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment"],"prefix":"10.3389","volume":"13","author":[{"given":"Franziska","family":"Marquard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Langebrake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietlinde","family":"Janson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maida","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrin","family":"Dadkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.421","article-title":"Acute myeloma kidney","volume":"48","author":"Winearls","year":"1995","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120005903","article-title":"The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients\u00a0with renal impairment: a prospective dose adjustment study","volume":"20","author":"Lichtman","year":"2002","journal-title":"Cancer Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30145-7","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"20","author":"Krens","year":"2019","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000775","article-title":"Haploidentical hematopoietic cell and kidney transplantation for hematological Malignancies and end-stage renal failure","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-022-00266-1","article-title":"Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis","volume":"11","author":"Hunter","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"175","author":"Sidana","year":"2023","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1288764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T08:58:37Z","timestamp":1699952317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1288764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":11,"alternative-id":["10.3389\/fonc.2023.1288764"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1288764","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"article-number":"1288764"}}